title: Observations following discontinuation of long-term denosumab therapy.
abstract: Stopping denosumab after 8 years of continued treatment was associated with bone loss during a 1-year observation study in patients who were not prescribed osteoporosis treatment. Bone loss was attenuated in patients who began another osteoporosis therapy. Treatment to prevent bone loss upon stopping denosumab should be considered.
  
  
  
  This study aimed to understand osteoporosis management strategies during a 1-year observational follow-up after up to 8 years of denosumab treatment in a phase 2 study.
  
  
  
  During the observational year, patients received osteoporosis management at the discretion of their physician and returned to the clinic for BMD assessment and completion of an osteoporosis management questionnaire. Incidence of serious adverse events and fractures was collected. Analyses were descriptive.
  
  
  
  Of 138 eligible patients, 82 enrolled in and completed the observation study. Most (65 [79%]) did not receive prescription osteoporosis medication, with "my doctor felt I no longer needed a medication" being the most common reason (23 [35%]). Of the 17 patients who took osteoporosis medications, 8 discontinued therapy during the observation study. In patients treated with denosumab for 8 years (N = 52), BMD decreased during the 1-year observation study (6.7% [lumbar spine], 6.6% [total hip]). Those who took osteoporosis medication during the observation study showed a smaller decline in BMD than those who did not. No new safety concerns were identified. Eight patients (9.8%), all of whom had at least one predisposing risk factor, experienced 17 fractures. This included seven patients who experienced one or more vertebral fractures.
  
  
  
  Consistent with denosumab's mechanism of action, treatment cessation led to reversal of the drug's effect on BMD and perhaps fracture risk. For patients who took osteoporosis therapy, bone loss was attenuated. For patients at high fracture risk, switching to another osteoporosis therapy if denosumab is discontinued seems appropriate.
authors.affiliation: Oregon Osteoporosis Center, 2881 NW Cumberland Road, Portland, OR, 97210, USA. mmcclung.ooc@gmail.com.|Australian Catholic University, Melbourne, Australia. mmcclung.ooc@gmail.com.
authors.forename: M R
authors.initials: MR
authors.lastname: McClung
authors.affiliation: Amgen Inc., Thousand Oaks, CA, USA.
authors.forename: R B
authors.initials: RB
authors.lastname: Wagman
authors.affiliation: Colorado Center for Bone Research, Lakewood, CO, USA.
authors.forename: P D
authors.initials: PD
authors.lastname: Miller
authors.affiliation: Amgen Inc., Thousand Oaks, CA, USA.
authors.forename: A
authors.initials: A
authors.lastname: Wang
authors.affiliation: New Mexico Clinical Research & Osteoporosis Center, Albuquerque, NM, USA.
authors.forename: E M
authors.initials: EM
authors.lastname: Lewiecki
mesh_terms: D000368:Aged; D005260:Female; D006801:Humans; D008875:Middle Aged; D015519:Bone Density / Q000187:drug effects; D050071:Bone Density Conservation Agents / Q000008:administration & dosage / Q000009:adverse effects; D000069448:Denosumab / Q000008:administration & dosage / Q000009:adverse effects; D004334:Drug Administration Schedule; D006621:Hip Joint / Q000503:physiopathology; D008159:Lumbar Vertebrae / Q000503:physiopathology; D015663:Osteoporosis, Postmenopausal / Q000150:complications / Q000188:drug therapy / Q000503:physiopathology; D058866:Osteoporotic Fractures / Q000209:etiology / Q000503:physiopathology / Q000517:prevention & control; D028761:Withholding Treatment; D017322:Clinical Trials, Phase II as Topic
chemical_list: D050071:Bone Density Conservation Agents; D000069448:Denosumab
keywords: Denosumab; Discontinuation; Osteoporosis; Treatment cessation